BMY vs. JNJ, ABBV, MRK, PFE, ZTS, RPRX, JAZZ, PRGO, CORT, and SUPN
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Bristol-Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Johnson & Johnson has a net margin of 46.34% compared to Bristol-Myers Squibb's net margin of -13.50%. Johnson & Johnson's return on equity of 36.79% beat Bristol-Myers Squibb's return on equity.
Johnson & Johnson received 13 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. However, 66.81% of users gave Bristol-Myers Squibb an outperform vote while only 64.89% of users gave Johnson & Johnson an outperform vote.
In the previous week, Bristol-Myers Squibb had 4 more articles in the media than Johnson & Johnson. MarketBeat recorded 55 mentions for Bristol-Myers Squibb and 51 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.33 beat Bristol-Myers Squibb's score of 0.29 indicating that Johnson & Johnson is being referred to more favorably in the news media.
76.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 4.8%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.1%. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb currently has a consensus price target of $57.73, indicating a potential upside of 14.55%. Johnson & Johnson has a consensus price target of $173.00, indicating a potential upside of 7.67%. Given Bristol-Myers Squibb's higher probable upside, research analysts clearly believe Bristol-Myers Squibb is more favorable than Johnson & Johnson.
Bristol-Myers Squibb has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Summary
Johnson & Johnson beats Bristol-Myers Squibb on 14 of the 20 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
